These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

109 related articles for article (PubMed ID: 23171334)

  • 1. Allelic combinations of immune-response genes as possible composite markers of IFN-β efficacy in multiple sclerosis patients.
    Kulakova OG; Tsareva EY; Boyko AN; Shchur SG; Gusev EI; Lvovs D; Favorov AV; Vandenbroeck K; Favorova OO
    Pharmacogenomics; 2012 Nov; 13(15):1689-700. PubMed ID: 23171334
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Allelic combinations of immune-response genes associated with glatiramer acetate treatment response in Russian multiple sclerosis patients.
    Tsareva EY; Kulakova OG; Boyko AN; Shchur SG; Lvovs D; Favorov AV; Gusev EI; Vandenbroeck K; Favorova OO
    Pharmacogenomics; 2012 Jan; 13(1):43-53. PubMed ID: 22111603
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Pharmacogenomics of multiple sclerosis: association of immune response genes polymorphism with copaxone treatment efficacy].
    Tsareva EIu; Kulakova OG; Makarycheva OIu; Boĭko AN; Shchur SG; Lashch NIu; Popova NF; Gusev EI; Bashinskaia VV; L'vov DV; Favorov AV; Ochs MF; Favorova OO
    Mol Biol (Mosk); 2011; 45(6):963-72. PubMed ID: 22295566
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparative pharmacogenetics of multiple sclerosis: IFN-β versus glatiramer acetate.
    Kulakova OG; Tsareva EY; Lvovs D; Favorov AV; Boyko AN; Favorova OO
    Pharmacogenomics; 2014 Apr; 15(5):679-85. PubMed ID: 24798724
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Immune response genes receptors expression and polymorphisms in relation to multiple sclerosis susceptibility and response to INF-β therapy.
    Karam RA; Rezk NA; Amer MM; Fathy HA
    IUBMB Life; 2016 Sep; 68(9):727-34. PubMed ID: 27346865
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Single-nucleotide polymorphisms in HLA- and non-HLA genes associated with the development of antibodies to interferon-β therapy in multiple sclerosis patients.
    Weber F; Cepok S; Wolf C; Berthele A; Uhr M; Bettecken T; Buck D; Hartung HP; Holsboer F; Müller-Myhsok B; Hemmer B
    Pharmacogenomics J; 2012 Jun; 12(3):238-45. PubMed ID: 21502966
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacogenomics of responsiveness to interferon IFN-beta treatment in multiple sclerosis: a genetic screen of 100 type I interferon-inducible genes.
    Cunningham S; Graham C; Hutchinson M; Droogan A; O'Rourke K; Patterson C; McDonnell G; Hawkins S; Vandenbroeck K
    Clin Pharmacol Ther; 2005 Dec; 78(6):635-46. PubMed ID: 16338279
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Chemokine receptor CCR5 in interferon-treated multiple sclerosis.
    Sellebjerg F; Kristiansen TB; Wittenhagen P; Garred P; Eugen-Olsen J; Frederiksen JL; Sørensen TL
    Acta Neurol Scand; 2007 Jun; 115(6):413-8. PubMed ID: 17511851
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Association study of promoter polymorphisms of interferon alpha and beta receptor subunit 1 (IFNAR1) gene and therapeutic response to interferon-beta in patients with multiple sclerosis.
    Hajian S; Mazdeh M; Nouri F; Roshanaei G; Soleimani M
    Mol Biol Rep; 2021 Aug; 48(8):6007-6013. PubMed ID: 34328599
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Genome-wide scan of 500,000 single-nucleotide polymorphisms among responders and nonresponders to interferon beta therapy in multiple sclerosis.
    Comabella M; Craig DW; Morcillo-Suárez C; Río J; Navarro A; Fernández M; Martin R; Montalban X
    Arch Neurol; 2009 Aug; 66(8):972-8. PubMed ID: 19667218
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Single-nucleotide polymorphisms in response to interferon-beta therapy in multiple sclerosis.
    Vandenbroeck K; Comabella M
    J Interferon Cytokine Res; 2010 Oct; 30(10):727-32. PubMed ID: 20836710
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Genome-wide pharmacogenomic analysis of the response to interferon beta therapy in multiple sclerosis.
    Byun E; Caillier SJ; Montalban X; Villoslada P; Fernández O; Brassat D; Comabella M; Wang J; Barcellos LF; Baranzini SE; Oksenberg JR
    Arch Neurol; 2008 Mar; 65(3):337-44. PubMed ID: 18195134
    [TBL] [Abstract][Full Text] [Related]  

  • 13. IFNAR1 and IFNAR2 polymorphisms confer susceptibility to multiple sclerosis but not to interferon-beta treatment response.
    Leyva L; Fernández O; Fedetz M; Blanco E; Fernández VE; Oliver B; León A; Pinto-Medel MJ; Mayorga C; Guerrero M; Luque G; Alcina A; Matesanz F
    J Neuroimmunol; 2005 Jun; 163(1-2):165-71. PubMed ID: 15885318
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Interferon gamma allelic variants: sex-biased multiple sclerosis susceptibility and gene expression.
    Kantarci OH; Hebrink DD; Schaefer-Klein J; Sun Y; Achenbach S; Atkinson EJ; Heggarty S; Cotleur AC; de Andrade M; Vandenbroeck K; Pelfrey CM; Weinshenker BG
    Arch Neurol; 2008 Mar; 65(3):349-57. PubMed ID: 18332247
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Genetic polymorphisms, their allele combinations and IFN-beta treatment response in Irish multiple sclerosis patients.
    O'Doherty C; Favorov A; Heggarty S; Graham C; Favorova O; Ochs M; Hawkins S; Hutchinson M; O'Rourke K; Vandenbroeck K
    Pharmacogenomics; 2009 Jul; 10(7):1177-86. PubMed ID: 19604093
    [TBL] [Abstract][Full Text] [Related]  

  • 16. CCR5 Δ32 and CTLA-4 +49 A/G Gene Polymorphisms and Interferon-β Treatment Response in Croatian and Slovenian Multiple Sclerosis Patients.
    Nekić J; Stanković Matić I; Rački V; Janko Labinac D; Vuletić V; Kapović M; Ristić S; Peterlin B; Starčević Čizmarević N
    Int J Mol Sci; 2024 Jul; 25(13):. PubMed ID: 39000519
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacogenomics of the response to IFN-beta in multiple sclerosis: ramifications from the first genome-wide screen.
    Vandenbroeck K; Matute C
    Pharmacogenomics; 2008 May; 9(5):639-45. PubMed ID: 18466107
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Role of differential expression of interferon receptor isoforms on the response of multiple sclerosis patients to therapy with interferon beta.
    Gilli F
    J Interferon Cytokine Res; 2010 Oct; 30(10):733-41. PubMed ID: 20874250
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacogenomic update on multiple sclerosis: a focus on actual and new therapeutic strategies.
    Foti Cuzzola V; Palella E; Celi D; Barresi M; Giacoppo S; Bramanti P; Marino S
    Pharmacogenomics J; 2012 Dec; 12(6):453-61. PubMed ID: 23044601
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Interferon-beta enhances monocyte and dendritic cell expression of B7-H1 (PD-L1), a strong inhibitor of autologous T-cell activation: relevance for the immune modulatory effect in multiple sclerosis.
    Schreiner B; Mitsdoerffer M; Kieseier BC; Chen L; Hartung HP; Weller M; Wiendl H
    J Neuroimmunol; 2004 Oct; 155(1-2):172-82. PubMed ID: 15342209
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.